Loading clinical trials...
Loading clinical trials...
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participant...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
CoMentis
NCT07571161 · Alzheimer Disease
NCT06847321 · Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
NCT06937229 · Alzheimer Disease, Agitation
NCT07633470 · Alzheimer Disease
NCT04579120 · Alzheimer Disease
Clinical Dept.
280 South San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions